Does Cosentyx Affect Heart Rate or Rhythm?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lists no direct effects on heart rate or rhythm in its prescribing information or clinical trials. Common cardiovascular events in trials were infrequent and similar to placebo, with no signals for bradycardia, tachycardia, or arrhythmias.[1][2]
What Do Clinical Trials Show on Cardiac Safety?
In phase 3 trials like FUTURE and MEASURE, involving over 5,000 patients, cardiovascular adverse events occurred in 1-2% of Cosentyx users versus placebo, mostly hypertension or ischemia, not heart rate/rhythm changes. ECG monitoring showed no clinically meaningful QT prolongation or rhythm disturbances.[2][3]
Any Reported Heart Rhythm Issues Post-Approval?
FDA adverse event reports via FAERS include rare cardiac mentions (e.g., palpitations in <0.1% of cases), but no causal link to Cosentyx. EMA reviews confirm no new rhythm signals in pharmacovigilance data.[1][4] Patients with pre-existing heart conditions were excluded from core trials, so real-world data in high-risk groups is limited.
How Does It Compare to Other Biologics Like Humira or Stelara?
Unlike TNF inhibitors (e.g., Humira), which carry boxed warnings for heart failure worsening, Cosentyx has no such alerts. IL-17 inhibitors like Cosentyx show neutral cardiovascular profiles versus JAK inhibitors (e.g., Xeljanz), which have atrial fibrillation risks in labels.[2][5]
Who Should Monitor Heart Rate on Cosentyx?
Patients with baseline arrhythmias or on cardioactive drugs (e.g., beta-blockers) report no interactions affecting rate/rhythm in studies. Routine ECG isn't required, but those with cardiovascular disease should have baseline assessments per guidelines.[1][3]
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Label for Secukinumab
[3]: NEJM: Secukinumab Phase 3 Trials (2014)
[4]: EMA Pharmacovigilance Report (2022)
[5]: Xeljanz Label (Pfizer)